Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $110 from $100 and keeps a Buy rating on the shares. The firm noted the FDA posted on its website that relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer has been approved. This comes over three months sooner than the July 11th PDUFA. The drug is now branded Lifyorli. Canaccord believes this extremely early action by the FDA demonstrates the significant impact on overall surgical that the drug has in the difficult to treat patient population.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Faces Investor Suit Over Relacorilant NDA Disclosure
- Corcept Therapeutics price target raised to $110 from $100 at Canaccord
- Corcept Wins FDA Approval for Lifyorli Ovarian Cancer Therapy
- Corcept confirms FDA approves Lifyorli for platinum-resistant ovarian cancer
- Corcept Rockets 48% after FDA Lifyorli Approval — What Does This Mean for CORT Stock?